Even in the United States, where several anti-obesity drugs have been approved, the prescription rates for these drugs are very low, and most cardiovascular guidelines still recommend lifestyle modifications as the only treatment for obesity to prevent ORCVDs [2,3,4]
10 At the Heart Failure Society of America (HFSA) 2023 Annual Scientific Meeting, trial investigators brought forth additional data fortifying the excitement surrounding the agents purported cardiovascular benefit, with results from a prespecified analysis demonstrating benefits of semaglutide observed in the trial were consistent across the spectrum of ejection fraction
Clinical trials show average monthly weight loss on semaglutide ranges from 1 to 4 pounds, depending on dose level and duration of treatment
By activating receptors in the brain that control appetite, Semaglutide promotes a natural feeling of satiety, which significantly decreases the urge to consume more calories than necessary
Yet the attention to what they do psychologically remains comparatively modest and catches many users by surprise